Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q86TM3 (cage)
 29,987 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two monoclonal antibodies, MLS 102, which recognizes cancer-associated mucin antigens, and MLS 103, which recognizes normal mucin, were used to isolate, by immunoaffinity chromatography, the corresponding antigens from cell lysates and spent medium of a human colorectal carcinoma cell line, LS 180. The MLS 102 antigen contained serine, threonine, and proline as major amino acids. The carbohydrate chains of the MLS 102 antigen were composed of O-linked NeuAc alpha 2----6GalNAc (56%), N-acetylgalactosamine (25%), and longer oligosaccharide chains. The MLS 103 antigen differed from the MLS 102 antigen in both amino acid and carbohydrate composition. Most O-linked oligosaccharides of the MLS 103 antigen were longer than the disaccharide found in the MLS 102 antigen. Immunostaining of LS 180 cells using MLS 102 and MLS 103 revealed that the cells are heterogeneous with respect to the expression of the antigens.
Cancer Res 1991 Jan 01
PMID:Characterization of mucin antigens recognized by monoclonal antibodies raised against human colon cancer cells. 198 95

The growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian malignancy, benign ovarian tumours and non-tumour related gynaecological conditions have been investigated using an ovarian carcinoma cell line (OAW 42), mesothelial cells (58MC) and rat kidney cells (NRK-49F). Colony stimulating activity (CSA) for tumour cells and transforming activity (TA) for mesothelial cells were weakly correlated, but whereas elevated TA was tumour-associated, CSA was not. However, TA was not cancer-associated and, although the difference between the mean TA values of benign and malignant cyst fluids was of borderline significance, some benign cyst fluids from cystadenomas showed high TA values. Higher levels of TA in the cystadenomas showed a significant correlation with the menopausal status of the patient and higher levels of TA in the malignant cyst fluid/peritoneal fluid groups were associated with more advanced disease. Results indicated that some fluids contained TGF-beta-like activity, but there was no direct evidence for the presence of TGF-alpha/EGF-like activity in the fluids. Heparin inhibited clonogenic growth of tumour cells but not mesothelial cells. The reduced CSA which was observed after treatment of fluids with both heparin and thrombin implicated coagulation factors in the manifestation of CSA. It was concluded that CSA in the fluids was due, at least partly, to fibrin coagulation, and TA was due to unknown growth factor(s) which may include TGF-beta-like activity. The results are discussed in the context of the aetiology of ovarian carcinoma, and the possible clinical significance of TA.
Br J Cancer 1991 Jan
PMID:A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours. 198 47

A total of 72 human leukemia-lymphoma cell lines were studied for reactivity with the monoclonal antibody (MAb) A7, an anti-human colon-cancer-cell-associated antigen reagent, by indirect membrane immunofluorescence. Nine of the 72 cell lines expressed the antigen recognized by A7 MAb. Five of the 34 T-cell lines, 2 of the 21 B-cell lines, and 2 of the 3 non-lymphoid-non-myeloid cell lines were reactive with A7 MAb. By means of SDS-PAGE and immunoblotting, the antigens isolated from both colon cancer cell lines (WiDr, SW1116 and LoVo) and leukemia cell lines (A3/KAWAKAMI, H9, RPMI 8226 and SPI-801) showed an identical MW of 42-43 kDa. The non-glycosylated antigen recognized by A7 MAb, which was expressed on both the colon cancer line (SW1116) and the leukemia line (H9) in the presence of tunicamycin, also showed an identical MW of 36 kDa. However, the quantity of the antigen in the leukemia cells was significantly lower than in the colon cancer cells. Although expression of this colon-cancer-associated antigen in the non-colon cancer cells is real, the significant expression of this antigen in colon-cancer cells makes it useful for clinical monitoring of colon cancer patients.
Int J Cancer 1991 Feb 01
PMID:Identification and characterization of a colon-cancer-associated antigen expressed on leukemia-lymphoma cell lines. 199 51

Adjuvant psychological therapy (APT) is a newly developed cognitive behavioural treatment which has been designed specifically to improve the quality of life of cancer patients by alleviating emotional distress and inducing a fighting spirit. We report a phase I/II study which evaluates APT in routine clinical practice. A consecutive series of 44 outpatients with various cancers referred for psychiatric consultation and receiving APT at the Royal Marsden Hospital was studied. Standardised self-report questionnaires were used to measure anxiety, depression and four principal categories of mental adjustment to cancer, namely, fighting spirit, helplessness, anxious preoccupation and fatalism. Statistical comparisons between pre-therapy scores and scores after an average of five APT sessions revealed significant improvement in anxiety, depression, fighting spirit, anxious preoccupation and helplessness. Fatalism scores showed the same trend, but the changes were smaller. Patients with advanced disease showed as much improvement as those with local or locoregional disease. Present results indicate improvement in both psychiatric symptoms and mental adjustment to cancer associated with APT. Whether this association is causal remains to be determined by randomised controlled trials. Such a trial is in progress.
Br J Cancer 1991 Feb
PMID:Evaluation of adjuvant psychological therapy for clinically referred cancer patients. 199 3

We examined the localization of squamous cell cancer associated antigens (SCCAA) in dysplasia, cancer in situ (CIS) and microinvasive SCC of the uterine cervix, since detection of SCCAA in these subjects is highly effective for early diagnosis. Anti-squamous cell cancer associated antibody (Anti SCCAAb IgG) was prepared by immunizing rabbits with specific components at around PI 6.1 that were originally purified from SCC of maxillary sinus. In this study, the following results were obtained by the immunoperoxidase method. (1) Eleven out of 15(73%) cases of dysplasia, 20 out of 26(77%) cases of CIS, 21 out of 24(88%) cases of Stage I, 13 out of 14(93%) cases of Stage II and 9 out of 10(90%) cases of Stage III-IV in the clinical stages of SCC showed positive staining, while controls of unrelated SCC were almost negative. (2) The SCCAA positive ratio was 2 out of 2 cases of small cell nonkeratinized type, 86% in large cell nonkeratinized type and 94% in Keratinized type of SCC. (3) The SCCAA was demonstrated on all the layers of stratified squamous epithelium in a lesion of CIS and some layers migrated to adjacent nonneoplastic lesion with lateral invasion in middle layer. These results suggest that the demonstration of SCCAA may be useful in diagnosing the malignant transformation of squamous epithelium in the early stage of SCC.
 ...
PMID:[Immunohistochemical studies on a new antigens associated with squamous cell cancer in oncogenesis of uterine cervical cancer]. 199 17

This two-site immunoradiometric assay for human parathyrin-related protein 1-86 (PTHRP1-86) in plasma uses a mouse monoclonal antibody to PTHRP1-34 coupled to cellulose particles for immunoextraction of N-terminal immunoreactivity, and a rabbit antiserum to PTHRP37-67 that is indirectly labeled with 125I-labeled PTHRP37-67 for quantifying the bound analyte. The detection limit of the assay is 0.23 pmol/L, corresponding to 0.4 pg (0.04 fmol) per tube, for a sample volume of 200 microL. Recovery of PTHRP1-86 added to serum is essentially quantitative, and within- and between-batch precision is 4.4% and 11.1%, respectively. PTH1-84, PTHRP18-34, PTHRP9-34, PTHRP1-34, and PTHRP37-67 do not cross-react in the assay at concentrations up to 2 nmol/L. Plasma concentrations of PTHRP1-86 were below or close to the detection limit of the assay in normal subjects and in patients with primary hyperparathyroidism, hypoparathyroidism, chronic renal failure, and normocalcemic malignancy. In 37 hypercalcemic patients with various malignancies, we found detectable PTHRP1-86 concentrations in 35 (95%, mean 7.4 pmol/L, range 0.46-24.7). The data support the proposed humoral role of PTHRP in cancer-associated hypercalcemia and suggest that the assay has clinical utility in the differential diagnosis of hypercalcemia.
 ...
PMID:Development and validation of an immunoradiometric assay of parathyrin-related protein in unextracted plasma. 203 20

Sialyl Lex-i (SLX) concentrations in the extracts of noncancerous and cancerous tissues of various human organs were determined by radioimmunoassay for detailed evaluation of SLX. Cancerous tissues had significantly elevated SLX concentrations compared with noncancerous tissues of various organs. Tissue SLX concentration of the cancerous part was significantly higher than that of the adjacent noncancerous part in the same tissue. There was no significant correlation between tissue SLX concentration and serum SLX level. Positive localization of SLX was clearly observed in such cancerous tissues by immunohistochemical study, although not in any noncancerous tissues. Each of the antigens: SLX, CA 19-9, carcinoembryonic antigen, and CA 125 showed a different distribution pattern in tissue concentration or localization in various organs. These results indicate that SLX may be a valuable cancer-associated antigen produced by malignant tissues, suggesting its clinical application as a tumor marker.
Cancer 1991 Jul 01
PMID:Elevated tissue concentrations of sialyl Lex-i in cancerous tissues compared with those in noncancerous tissues of various organs. 204 31

Short-term cultures from 12 oral squamous cell carcinomas were cytogenetically investigated. A normal karyotype was found in 3 tumors, 2 of which had many nonclonal changes. Clonal chromosome abnormalities were detected in the remaining 9 cases, in 6 of them in the form of 2 or 3 abnormal clones. In 5 cases the different clones were cytogenetically unrelated, suggesting a multiclonal origin. Numerous additional nonclonal changes were present in 4 of the 9 tumors with clonal aberrations. None of the structural aberrations, clonal or nonclonal, were found in more than one case; nor did any of the rearrangements correspond to cancer-associated aberrations known from other tumors. The aberration breakpoints of the present series and of previously reported tongue cancer clustered to bands 1p32, 1p22, 1p11, 1q21, 1q23, 1q25, 1q32, 1q42, 1q44, 2q31, 3p11, 4q35, 7p22, 11p15, 11q13, 12q24, and 17q25.
Genes Chromosomes Cancer 1990 Jan
PMID:Unrelated clonal chromosomal aberrations in carcinomas of the oral cavity. 208 16

Detection of cancer-associated antigens in feces by the method of binding inhibition ELISA using monoclonal antibodies were performed in sixty patients with colorectal cancer; seventy with non-malignant gastrointestinal diseases: and one hundred healthy individuals. Monoclonal antibodies used were: anti-colonic cancer CL-2, CL-3, and anti-pancreatic cancer PS-9, PS-10. The level of cancer-associated antigens detected in feces were significantly higher in patients with colorectal cancer than that of non-malignant GI diseases or healthy individuals. The positive rate of the antigens in colorectal cancer patients and normal individuals were: 61.1% vs. 7% as detected by CL-2; 53.4% vs. 9% by CL-3; 55% vs. 8% by PS-9; and 53.3% vs. 8% by PS-10. When a "cocktail" of CL-2, PS-9, and PS-10 was used, the positive rate was 92.5% in cancer patients, and 14% in control group. Cancer-associated antigens were found to be positive in all seven early staged (Duke's A) colorectal cancer patients. These results indicate the value of assaying cancer-associated antigen in feces as an aid to the diagnosis of colorectal cancer, especially in the early stage.
 ...
PMID:[Value of fecal detection of cancer-associated antigens using monoclonal antibodies in the diagnosis of colorectal cancer]. 208 18

There have been many attempts to develop stochastic multistage models for cancer. The models relate hypothesized biological processes occurring at the cellular level to the occurrence of tumors at the experimental or epidemiologic level of individuals in a population. The existing models fit a variety of data, but none is fully satisfactory and they are in some ways inconsistent with each other. Recently, substantial new data have become available on the nature of cancer-associated mutations observed directly at the cellular level. These data suggest that the number of stages may be greater and more variable among individual tumors of the same organ than has been thought. There may be many pathways to cancer, and the mutations responsible may not constitute a fixed set or sequence. This pattern resembles the genetics of quantitative rather than qualitative traits, and may also be consistent with the variable histology and behavior of tumors of a given organ. Simulations using such models suggest that cancer in the general population may have such heterogeneous etiology, a possibility that has important implications for screening, risk projection, and prevention. Risk-generating processes of a rather generic kind may generate similar hazard functions for diverse chronic diseases in the age ranges often used in epidemiologic studies. This phenomenon raises questions about the purpose and interpretation of statistical epidemiologic models.
 ...
PMID:Cancer models and cancer genetics. 209 Feb 78


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>